Ba/F3-KIT D816V is sensitive to PKC-412 but not to imatinib. Plotted is the percentage of ³H-thymidine incorporation in drug-treated wells relative to no drug controls. Cells were treated with imatinib (dashed lines, ○) or PKC412 (solid line, •) for 24 hours in the presence of 10 ng/mL IL-3 and the absence of recombinant human stem cell factor (SCF). Plotted is the percent ³H-thymidine incorporation in drug-treated wells relative to no drug controls. Data are the mean of triplicates (plot standard deviation). PKC412 IC₅₀ 30 nM-40 nM.